Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Maintenance and Reinduction Chemotherapy With Avastin in Metastatic Colon Cancer: The MARTHA (SICOG 0803) Trial
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more tumor cells.
PURPOSE: This phase III trial is studying how well giving induction therapy with bevacizumab together with combination chemotherapy with or without capecitabine followed by bevacizumab maintenance therapy in treating patients with metastatic colorectal cancer that cannot be removed by surgery.
연구 개요
상세 설명
OBJECTIVES:
Primary
- To compare two strategies of induction bio-chemotherapy followed by the same maintenance biotherapy in terms of time to failure in patients with previously untreated metastatic colorectal cancer.
Secondary
- To compare the two arms of treatment in terms of response rate, duration of responses, progression-free survival, safety, and quality of life of these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to treatment center, performance status (0 vs 1), and number of metastatic sites (1 vs ≥ 2). Patients are randomized to 1 of 2 induction therapy arms.
- Arm I: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
In both arms, patients achieving stable disease after completion of 6 months of induction therapy proceed to maintenance therapy.
- Maintenance therapy: Patients receive bevacizumab IV over 30-90 minutes every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
During or after completion of maintenance therapy, patients with tumor regrowth that is not classified as disease progression from baseline and who achieved partial or complete response during or after their induction therapy proceed to reinduction therapy.
- Reinduction therapy: Patients receive B-FOLFIRI as described previously. Quality of life is assessed at baseline, every 3 months during induction therapy, and at discontinuation of study therapy.
After completion of study therapy, patients are followed for up to 2 years.
연구 유형
등록 (예상)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Naples, 이탈리아, 80131
- 모병
- Southern Italy Cooperative Oncology Group
-
연락하다:
- Pasquale Comella, MD
- 전화번호: 39-81-590-3227
- 이메일: pasqualecomella@libero.it
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed colorectal cancer
- Metastatic disease that is not amenable to surgery
- At least one measurable lesion according to RECIST criteria
- No untreated brain metastases or spinal cord compression
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy ≥ 12 weeks
- Hemoglobin ≥ 9.0 g/dL
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and/or ALT ≤ 2.5 times ULN (< 5 times ULN if liver metastases present)
- Alkaline phosphatase ≤ 2.5 times ULN (< 5 times ULN if liver metastases present)
- PT-INR/PTT < 1.5 times ULN
- Creatinine clearance > 50 mL/min OR serum creatinine ≤ 1.5 times ULN
- Proteinuria on dipstick urinalysis < 2+ OR 24-hour urine protein ≤ 1g
- Not pregnant or nursing
- Negative pregnancy test
- Must be accessible for treatment and follow-up
- No history of inflammatory bowel disease and/or acute or subacute bowel occlusion
- No serious non-healing wound, ulcer, or bone fracture
- No evidence of bleeding diathesis or coagulopathy
- No uncontrolled hypertension
No clinically significant cardiovascular disease including any of the following:
- Cerebrovascular accident within the past 6 months
- Myocardial infarction within the past 6 months
- Unstable angina
- New York Heart Association grade II-IV congestive heart failure
- Serious cardiac arrhythmia requiring medication
- No known allergy to Chinese hamster ovary cell proteins or any of the components of the study medications
- No other malignancy within the past 5 years except basal cell and squamous cell skin cancer or carcinoma in situ of the cervix
- No significant traumatic injury within the past 28 days
- No substance abuse or medical, psychological, or social conditions that may interfere with participation in the study or the evaluation of study results
- Able to swallow oral medications
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 6 months since prior adjuvant treatment
- No prior irinotecan and/or bevacizumab during prior adjuvant therapy
- No prior cytotoxic drugs for the metastatic disease
- More than 10 days since prior and no concurrent anticoagulants for therapeutic purposes
- No chronic, daily treatment with high-dose aspirin (> 325 mg/day) or other medications known to predispose to gastrointestinal ulceration
- No treatment with any investigational drug within the past 30 days
- No major surgical procedure or open biopsy within the past 28 days or anticipated need for a major surgical procedure during the course of the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Arm I
Patients receive bevacizumab IV over 30-90 minutes on day 1.
Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
|
주어진 IV
주어진 IV
주어진 IV
주어진 IV
|
|
실험적: Arm II
Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14.
Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
|
주어진 IV
주어진 IV
주어진 IV
구두로 주어진
주어진 IV
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
|---|
|
Time to failure of strategy
|
2차 결과 측정
결과 측정 |
|---|
|
무진행 생존
|
|
응답 기간
|
|
RECIST 기준에 따른 응답
|
|
Safety according to NCI CTCAE v3.0
|
|
Quality of life as assessed by EORTC QLQ-C30 questionnaire (v 3.0) at baseline, every 3 months during induction chemotherapy, and at discontinuation of treatment
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Pasquale Comella, MD, Istituto Nazionale per lo Studio e la Cura dei Tumori
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CDR0000617983
- SICOG-0803
- EudraCT-2008-004890-17
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .